Early detection and treatment of testicular cancer is key to beating the disease, a urology specialist says.
Yet many men who feel something abnormal in a testicle wait a few months before seeing a doctor.
But, when diagnosed while still confined to the testicle, the five-year survival rate for testicular cancer is 99 percent, Dr. Jay Raman, chief of urology at Penn State Medical Center said in a university news release.
“I think part of it is the macho man complex—that everything is fine. Then you add on top of that the fact that it is a sensitive area, and they may have some embarrassment about it,” Raman said.
Men who know about testicular cancer may also be concerned that surgical removal of the testicle is the best way to cure the disease.
“So they wait to see if it gets better on its own. But sometimes they wait and wait, until they’ve waited too long,” Raman said.
About 9,000 new cases of testicular cancer are diagnosed each year in the United States, according to Raman. Risk factors include being white and having a testicle that didn’t descend when younger. Since these risk factors are not preventable, the best thing to do is be aware of the risk and know the symptoms of cancer.
All men should do a testicular self-exam at least every six months, Raman advised.
“What you are feeling for is that both testicles have the same contours—relatively smooth and soft, kind of the consistency of a hard-boiled egg or the palm of your hand,” he said. “If you notice anything firm, or lumps or bumps—something that is different on one side than the other—you should seek medical attention right away.”
Surgery to remove the testicle is the most common treatment. If the cancer is confined to the testicle, exams and blood work may be the only follow-up patients require. If the cancer has spread beyond the testicle, chemotherapy and radiation may be necessary, he explained.
“The most important thing to know is that cure rates are directly tied to how early you find it,” Raman said.
Testicular cancer occurs most often in young men, and they need to know the signs of the disease, a urologist says.
Testicular cancer is relatively rare—about 9,000 new cases will be diagnosed this year in the United States—but it is the most commonly diagnosed cancer in males aged 15 to 40.
It’s a highly treatable disease, especially when diagnosed early, according to testicular cancer specialist Dr. Aditya Bagrodia, an assistant professor of urology at University of Texas Southwestern Medical Center in Dallas.
“Embarrassment about symptoms and even confusion with sexually transmitted diseases can prevent some young men from seeking medical help when the disease is at its earliest, most curable stage,” Bagrodia said in a medical center news release.
Signs of testicular cancer include: painless swelling or a mass about the size of a pea or marble in a testicle; a feeling of heaviness in the scrotum; a dull ache in the groin or scrotum; and breast tenderness or growth.
Only about 10 percent of patients have pain in the testicles.
If the cancer spreads to other parts of the body, patients may develop back pain, swelling in lymph nodes in the neck, difficulty breathing, chest pain or cough.
Men who are at high risk for testicular cancer should do a monthly self-exam. Risk factors include: family history of testicular cancer; personal history of testicular cancer; undescended testicle at birth, and infertility, Bagrodia explained.
“Diagnosis at an early stage can mean the difference between a straightforward surgical cure and having to potentially undergo chemotherapy, radiation and multiple surgeries,” he added.
Compared with other types of cancer, testicular cancer is rare. But testicular cancer is the most common cancer in men in the U.S. between the ages of 15 and 35.
Approximately 9,910 new cases of testicular cancer will be diagnosed in the U.S. in 2022, and 460 people will die from the disease, according to the American Cancer Society.
Testicular cancer occurs in the testicles, which are inside the scrotum, underneath the penis. The testicles produce male sex hormones and sperm for reproduction.
Risk factors for testicular cancer include an undescended testicle; abnormal testicle development; a family history of testicular cancer; and age, with those 15 to 35 most commonly affected. Also, testicular cancer is more common in white men than Black men.
Signs and symptoms of testicular cancer include:
A lump or enlargement in either testicle.
A feeling of heaviness in the scrotum.
A dull ache in the abdomen or groin.
A sudden collection of fluid in the scrotum.
Pain or discomfort in a testicle or the scrotum.
Enlargement or tenderness of the breasts.
Testicular cancer is treatable, even when cancer has spread beyond the testicle. If you’ve been diagnosed with testicular cancer, your treatment will be based on several factors, including the type and stage of cancer, and your overall health and preferences. Treatment can include surgery, radiation therapy or chemotherapy.
Over 1,500 riders across Canada will be dressed in their finest atop vintage motorbikes as they raise funds and awareness for men’s health
To take place in over 29 cities across Canada including: Toronto, Vancouver, Edmonton, Calgary, Ottawa, Montreal, Halifax
More than 100,000 unite in world’s largest 24-hour motorcycle event
Over $2.5 million CAD raised through DGR by Canadian riders since 2016
TORONTO, May 20, 2022 /CNW/ – After two years of disruption and social distancing, over 1,500 motorcyclists coast-to-coast from across Canada will join fellow bike enthusiasts around the world on Sunday, May 22nd for the 11th annual Distinguished Gentleman’s Ride (DGR). The global event brings together over 90,000 members of the motorcycle community from over 100 countries and 800 cities worldwide, united in their common goal to raise funds and awareness for Movember, the leading men’s health charity.
For the first time since 2019, riders will once again be dressed in their most eye-catching dapper gear and atop their classic, vintage motorbikes, finally taking to the roads together as a group, no longer having to participate in solo rides due to pandemic restrictions. In Canada, riders across 29 cities will take part including: Bathurst (NB), Berwick (NS), Calgary (AB), Drummondville (QC), Edmonton (AB), Gibsons (BC), Halifax (NS), Hamilton (ON), Kelowna (BC), Kindcardine (ON), Ladysmith (BC), London (ON), Moncton (NB), Montreal (QC), Niagara Falls (ON), Ottawa (ON), Parksville (BC), Pickering (ON), Quebec City (QC), Regina (SK), Rimouski (QC), Shediac (NB), Sherbrooke (QC), Squamish (BC), Toronto (ON), Vancouver (BC), Vernon (BC), Victoria (BC) and Winnipeg (MB).
Since its inception in 2012, DGR has connected over 400,000 riders of classic and vintage style motorcycles and have raised more than $40 million CAD for men’s health, specifically prostate cancer, and men’s mental health. Since 2016, the event has partnered with Movember, which has played a significant role in funding programs that have supported men around the world.
Locally, over $2.5 million CAD has been raised for Movember by Canadian riders since the organization first came on board as DGR’s official charity partner in 2016. Funds raised have gone into projects such as prostate cancer research and support for men’s mental health. In 2021, a portion of the funding was used to support the motorcycling community itself, with over $1 million CAD injected into nine projects selected from ideas crowd-sourced around the world as part of the DGR Social Connections Challenge (DGRSCC). The projects have been rolling out over the last 12-month, with the aim of improving social connectedness, life satisfaction and mental wellbeing among motorcycle riders.
Founder of The Distinguished Gentleman’s Ride, Mark Hawwa comments on the impact the event and Movember are making on men’s health. “Over the last ten years and 11 DGR’s later, we have raised a tremendous amount for men’s health, developing strong community connections and cause-related programs that have helped thousands of men around the world. This year, we have continued to fund our DGR Social Connections Challenge and the Veterans and First Responders Grant, in partnership with Movember. These programs have supported the motorcycling communities within various cities around the world, and have shown support in-kind to the veterans, police, fire, and emergency services who have sacrificed for their communities and countries. We are proud to be able to support them in return.”
Movember CEO, Michelle Terry, discusses the importance of bringing the DGR community together in 2022. “The DGR community has always instinctively understood the importance of having strong social connections as a keyway of maintaining mental wellbeing. Over the last decade, the rides have come to symbolise the desire of the community to stand together and support each other through tough times. After two years of having to ride solo due to pandemic restrictions, we are delighted to see the community able to ride together again, shoulder to shoulder, raising vital funds for men’s health projects.”
This year, DGR is excited to continue its partnership with Triumph Motorcycles, who have offered a one-of-a-kind Spirit of ’59 prize in collaboration with Gibson Guitars. This partnership brings the 1950’s history of cafe racer culture to the 2022 Distinguished Gentleman’s Ride with a unique prize for the event. The 1959 Legends custom edition Les Paul Standard Reissue and Spirit of ’59 Bonneville T120, featuring a host of beautiful hand-detailed custom touches, designed, and applied in Triumph’s factory workshop.
Prize competitions for the 2022 campaign are still open for you to be involved in. To find out more, visit https://www.gentlemansride.com/about/prizes. The final date for donations and competitions is Sunday 5th June 2022. The Distinguished Gentleman’s Ride 2023 will return on Sunday May 21st, 2023.
Movember is the leading charity changing the face of men’s health on a global scale. The charity raises funds to deliver innovative, breakthrough research and support programs that enable men to live happier, healthier, and longer lives. Committed to disrupting the status quo, millions have joined the movement, helping fund over 1,250 projects focusing on mental health and suicide prevention, prostate cancer, and testicular cancer. In addition to tackling key health issues faced by men, Movember is working to encourage men to stay healthy in all areas of their life, with a focus on men staying socially connected and becoming more open to discussing their health and significant moments in their lives. The charity’s vision is to have an everlasting impact on the face of men’s health. To donate or learn more, please visit movember.com.
ABOUT THE DISTINGUISHED GENTLEMAN’S RIDE
The Distinguished Gentleman’s Ride unites classic and vintage style motorcycle riders all over the world to raise funds and awareness for prostate cancer research and men’s mental health. The Distinguished Gentleman’s Ride was founded in Sydney, Australia in 2012 by Mark Hawwa. After inspiration from a photograph featuring classic suits and vintage motorcycles, Mark decided a themed ride would be a great way to combat the often-negative stereotype of motorcyclists and connect the global motorcycling community and to raise funds for a cause important to every rider. For more information, visit www.gentlemansride.com.
First established in 1902, Triumph Motorcycles celebrated 118 years of motorcycle manufacture in 2020. For more than three decades, Triumph Motorcycles has been based in Hinckley, Leicestershire, and has produced iconic bikes that perfectly blend authentic design, character, charisma, and performance. The Triumph Modern Classic motorcycle family represents the quintessence of The Distinguished Gentleman’s Ride spirit: elegant, iconic, characterful, and built for the ride.
The cryopreservation equipment market is expected to reach US$ 12,489.84 million by 2028 from US$ 6,358.65 million in 2022; it is estimated to grow at a CAGR of 11.9% from 2022 to 2028.
The factors such as growing acceptance for regenerative medicine and increasing need of biobanking practices are contributing to the market growth. However, the stringent regulatory requirements hinder the cryopreservation equipment market growth.
Cryopreservation is a technique employed to minimize cell damage caused during freezing and storage of biological materials such as tissue, bacteria, fungi, virus, and mammalian cells. Tissues and genetically stable living cells preserved via cryopreservation can be used in research and other biomedical applications. The equipment required for cryopreservation includes cryopreservation systems, cryoware, accessories, and cryogen.
Cryopreservation plays an important part in the field of regenerative medicine as it facilitates stable and secure storage of cells and other related components for a prolonged time. Regenerative medicine enables replacing diseased or damaged cells, tissues, and organs by retrieving their normal function through stem cell therapy.
Owing to the advancements in the medical technology, stem cell therapy is now being considered as an alternative to traditional drug therapies in the treatment of a wide range of chronic diseases, including diabetes and neurodegenerative diseases.
Based on type, the global cryopreservation equipment market is segmented into freezers, sample preparation systems, and accessories. In 2021, the freezers segment held the largest share of the market, and it is expected to register the highest CAGR in the market during 2022-2028. In ultracold freezers, liquid nitrogen is used for the successful preservation of more complex biological structures by virtually seizing all biological activities.
Cryogen Type Insights
Based on cryogen type, the global cryopreservation equipment market is segmented into liquid nitrogen, oxygen, liquid helium, argon, and others. In 2021, the liquid nitrogen segment held the largest share of the market; the market for this segment is further expected to grow at the highest CAGR during 2022-2028. Liquid nitrogen is a nonmechanical method of cells preservation. Large thermos-like containers are used to house either racks or shelves that hold cryogenic vials.
Based on application, the global cryopreservation equipment market is segmented into cord blood stem cells, sperms, semen & testicular tissues, embryos and oocytes, cell and gene therapies, and others. In 2020, the cord blood stem cells segment held the largest share of the market. Moreover, the market for the sperms segment is expected to register the highest CAGR in the market during 2022-2028. In recent years, public cord banking has been promoted over private cord banking. Various centers across the world are performing cord blood stem cell transplantation as a part of the management of genetic, hematologic, immunologic, metabolic, and oncologic disorders, among others, which is bolstering the growth of the market for the public cord banking segment.
End User Insights
Based on end user, the cryopreservation equipment market is segmented into stem cell banks, biotechnology and pharmaceuticals organizations, stem cell research laboratories, and others. The biotechnology and pharmaceuticals organizations segment held the largest market share in 2020, and it is further expected to be the largest shareholder in the market by 2028. Cryopreservation has become an integral part of the manufacturing process of many cellular therapies as it sometimes precedes cell culture (by preserving the starting cellular material before beginning large-scale manufacturing) and generally follows cell expansion.
1208 Productions Continues Pledge to Raise a Quarter Million Dollars with NFTs for FCancer in 2022
LOS ANGELES, Aug. 15, 2022 /PRNewswire/ — FCancer, the 501(c)3 nonprofit dedicated to advancing health equity through early detection and prevention programs and by providing resources to navigate, manage and cope with cancer, and 1208 Productions are excited to announce that they will continue on their mission of pushing the boundaries of NFTs with a goal to raise over $250,000 for the organization in 2022 through exclusive NFT releases. Launching this summer, FCancer x 1208 Productions will be unveiling LayDeez [https://twitter.com/LayDeezNFT] a new project for women, led by women in support of breast cancer awareness and research.
How It Started:
Over the last year, the phrase “NFTs” (or Non Fungible Tokens) has become a buzzword amongst design buffs, hypebeasts, tech enthusiasts and aspiring art collectors alike. With the intention of using this trending medium for good, in late 2021 long-time techpreneur Michael Roberts shifted the focus of his successful web development brand 1208 Productions to create NFTs that channel creativity with a positive impact.
Roberts’ first endeavor in the NFT world, Deez Nuts (Official Nuts) was a playful, cheeky approach that served to raise awareness, and ultimately help combat a cause near and dear to his heart, testicular cancer. The first drop sold out over 10,000 pieces in the first two hours, including the rare Deez Nuts x FCancer ‘Nut’ which saw $50,000 donated back to the organization’s critical work. The success of this Robert’s first NFT sale ignited the entrepreneur to officially commit to a goal of raising a quarter million dollars for FCancer by the end of the year.
Most recently, Deez Nuts partnered with: FCancer once again to launch a digital Arcade and Casino, known as the Nutcade and Nutsino, in which 1208 Productions committed to donating a portion of profits back to the organization’s critical work in advancing health equity through early detection and preventions programs.
“It has been such a wonderful experience working with the Deez Nuts / LayDeez team! Not only are they focused on providing opportunities for women in web3, they’re also focused on using their platform and projects for good. They have already donated 50k to FCancer in 2021 and pledged another 50k this year. We are so excited to grow this relationship and continue making an impact in the Cancer space with the Deez Nuts team!” – Julie Greenbaum Co-Founder FCancer
Women Take the Lead: Working Towards The Quarter Million Dollar Pledge
In celebration of unstoppable feminine forces, 1208 Productions brought in a robust female leadership team to oversee a female focused charitable initiative. This new NFT collection will include special 1 for 1 characters designed in collaboration with FCancer which represent women who have endured a mastectomy to empower, uplift and represent the strength of women at every stage of their cancer journey.
LayDeez has pledged to donate $50,000 of proceeds from this NFT drop to FCancer to help and support those impacted by Breast Cancer and other female related cancer
Techpreneur, Michael Roberts started 1208 Productions 6 years ago to follow his passion and utilize his creativity to build video games. The company’s first mobile game was picked up by both Apple and Google worldwide and eventually gained the attention of some of the top game publishers in the world. One of 1208’s first two mobile games held a #1 game spot on a global level and garnered over 300 million downloads among their portfolio.
In 2021, Roberts transited 1208 Productions out of mobile game development to channel the same creativity with a charitable impact. Over the past year, 1208 Productions has offered technical and creative support to renowned drops including JRNY and NEO Tokyo and has put NFT and Play to Earn Games as their primary focus for the foreseeable future. 1208 Productions is the leading creative force behind Deez Nuts, LayDeez and more. For more information, please visitwww.1208productions.com.
FCancer is a 501(c)3 nonprofit in the United States and a registered Canadian charity dedicated to improving health outcomes by providing early detection, prevention, and support programs that advances health equity for individuals and communities affected by cancer. For more information, please visit www.letsfcancer.org.
– Clinicians agree that evidence supports testing benefits for all –
SAN FRANCISCO, Sept. 15, 2022 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology, underscoring the importance of universal germline testing for all patients with cancer (solid tumors). The paper reports a meta-analysis of multiple clinical publications supporting universal testing, independent of age, stage, family history or type of cancer. It reports that for cancer types such as pancreatic and ovarian where universal genetic testing is already recommended, 13% and 20% of patients (respectively) have identifiable actionable heritable gene mutations,2. In comparison, the actionable inherited gene mutation rate for patients with other cancer types is similar: breast 11%, endometrial 13%, prostate 14%, kidney 13%, bladder 14%, testicular 13%, colorectal 13%, liver 14%, and stomach 14%.
Furthermore, it reports that between 5-13% of patients with cancer with heritable gene mutations are missed by current restrictive testing guidelines and are unable to benefit from associated precision treatment and clinical trial benefits. First, allowing all patients to receive germline testing, without restrictive guidelines, affords patients access to precision therapies, clinical trials and other risk reducing interventions that can improve outcomes, and even extend overall patient survival1. Second, genetic testing informs surveillance and risk reduction for future cancers in patients already affected by cancer. Third, cascade testing helps alert their family members of an increased risk for cancer, so they too can then take advantage of monitoring and risk reducing interventions. Consistent with the Cancer Moonshot 2.0 and the President’s Cancer Panel report 2022, the expert consensus concludes that current evidence supports the implementation of universal germline genetic testing for all patients with cancer (solid tumors).
“This consensus from nationally recognized, cancer genetics clinical experts reinforces the current guidelines that universal genetic testing be offered in all patients with ovarian and pancreatic cancer and either be offered or considered in all patients with colorectal,” said Ed Esplin, MD, PhD, FACMG, FACP, clinical geneticist at Invitae. “More importantly, this is a call to all guidelines committees, insurer medical policy makers and the President’s Cancer Moonshot Cabinet to make universal genetic testing available to potentially reduce mortality and improve the lives of all patients with cancer.”
“The PROCLAIM study demonstrates the clinical utility of universal germline genetic testing in patients with prostate cancer. Current NCCN guidelines preclude some prostate cancer patients from receiving germline testing, thus depriving these patients of the potential to receive precision-based therapies and specific clinical trial eligibility, while perpetuating healthcare disparities among historically underrepresented populations. The PROCLAIM data supports universal genetic testing for prostate cancer patients. We should expeditiously eliminate barriers to gene-based precision therapies to optimize patient outcomes and accelerate equitable access to care,” said Neal Shore, MD, urologist and medical director, Carolina Urologic Research Center.
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.
Worldwide, there were an estimated 18.1 million new cases of cancer in 2018, with one in four men and one in five women developing the disease. In addition, there were 43.8 million persons living with cancer in 2018 who were diagnosed within the last five years.
“The INTERCEPT study has shown the prevalence and clinical utility of germline genetic testing is virtually the same across 14 cancer types, even those cancers not traditionally considered hereditary. This data supports universal genetic testing not only for colorectal cancer, but patients with all cancer types, to potentially improve their treatment and future cancer prevention for them and their family members,” said Jewel Samadder, MD, enterprise co-leader precision/individualized cancer medicine, Mayo Clinic Comprehensive Cancer Center.
Restrictive guidelines can lead to disparities in cancer care. Offering germline genetic testing to all patients with cancer at diagnosis may help reduce inequities in cancer care by expanding access for all patients to precision therapy or clinical treatment trials.
“The prevalence of pathogenic variants in cancer susceptibility genes for which there are management guidelines is similar among patients with all types of solid tumors, therefore, it does not makes sense that current guidelines only recommend germline genetic testing for all patients with ovarian, pancreatic, and recently, colorectal cancers. This information has the potential to affect the treatment of these individuals’ current cancers. In addition, it has the potential to allow for the prevention or early detection of future cancers in both these patients and their family members,” said Heather Hampel, MS, CGC, professor, Department of Medical Oncology & Therapeutics Research, City of Hope.
About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices. For more information, visit the company’s website at invitae.com.
Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential benefits of universal genetic testing for all patients with cancer; and that restrictive guidelines can lead to disparities in cancer care. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s history of losses; the company’s ability to compete; the company’s failure to manage growth effectively; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
IU Simon Comprehensive Cancer Center joins Caris’ extensive network of leading cancer institutions committed to utilizing clinical data to advance patient care and outcomes
IRVING, Texas, Sept. 28, 2022 /PRNewswire/ — Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
Established in 1992, the IU Simon Comprehensive Cancer Center is Indiana’s sole National Cancer Institute (NCI)-designated comprehensive cancer center. Its nearly 300 researchers conduct all phases of cancer research, from laboratory studies to clinical trials to population-based studies that address environmental and behavioral factors that contribute to cancer.
“We are proud to become a member of the Caris Precision Oncology Alliance,” said Kelvin Lee, M.D., director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. “We are eager to collaborate with many of the nation’s leading cancer centers on precision oncology research as we all work together to improve patient outcomes.”
The IU Simon Comprehensive Cancer Center conducted the ground-breaking work that led to the 95 percent cure rate for testicular cancer and pioneered lifesaving cord blood transplantation. The center has more than 130,000 adult outpatient visits each year, offers more than 300 active clinical trials at any time, and provides training for nearly 2,000 students, residents, and fellows every year.
“We are delighted to welcome IU Simon Comprehensive Cancer Center to the growing Precision Oncology Alliance network,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “The research, innovation, and patient-centric care that IU Simon Comprehensive Cancer Center clinicians and researchers lead are aligned with the POA vision of improving the outcomes of all patients affected with cancer. Together, we will be stronger, and do better.”
The Caris Precision Oncology Alliance includes 71 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1 million data points per patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris’ latest advancement is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
About IU Simon Comprehensive Cancer Center
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center is Indiana’s only National Cancer Institute-designated Comprehensive Cancer Center and one of only 53 in the nation. The comprehensive designation recognizes the center’s excellence in basic, clinical, and population research, outstanding educational activities, and effective community outreach program across the state. It is also home to the world’s only healthy breast tissue bank and the Center for Global Oncology and Health Equity, and it serves as the central hub for cancer research and education across Indiana University. To learn more, visit IU Simon Comprehensive Cancer Center.
“Shavetopia” will allow Roblox users to purchase facial hairstyles for their online avatars this fall
STAMFORD, Conn., Oct. 26, 2022 /PRNewswire/ — Philips Norelco recently launched “Shavetopia” – an interactive hub on Roblox that gives users the ability to choose from a variety of avatar facial hairstyles. This venture on Roblox, a global platform connecting over 50 million people daily through shared immersive experiences, helps extend the men’s grooming brand and important social causes it supports to the metaverse.
Through November 30th, 2022, everyone – regardless of gender identity or ability to grow a moustache – is encouraged to participate in Movember virtually by purchasing one of Movember’s facial hairstyles in the Avatar Marketplace for their Roblox avatar. Users can view and try on facial
hairstyles in Shavetopia before purchasing for their avatars.
“Shavetopia” provides a 3D online space for Roblox visitors to try virtual hairstyles, play mini-games and spend time with friends and family as they try out new looks to embrace a new sense of virtual identity. Each game will feature unique Philips Norelco power-ups, which provide the opportunity for Roblox community members to wear their selected facial hairstyles and gain unique bonuses. Shavetopia has portals to three fan favorite experiences on Roblox: Retail Tycoon 2, Emergency Response: Liberty County, and Tower Defense Simulator.
“With our purpose of improving people’s lives at the forefront of everything we do, Philips is taking our philanthropic efforts into exciting new territory by applying that purpose to self-expression and confidence in both the real world and virtual worlds,” said Rafael Viestel da Silva, Philips Grooming and Beauty Marketing Director. “We’re excited to extend our partnership with Movember to Roblox, with shared goals of empowerment and working together for social good.”
Individual expression and appearance are critical pieces of how we express ourselves, and Philips Norelco wants to empower people to express their true selves, both in the physical and digital worlds. Driven by this purpose, is an extension of the partnership with Movember, which began in 2021 to support important men’s health causes.
Movember aims to support men’s mental and physical health through research, community outreach and initiatives such as encouraging guys to grow their Mo each November to raise awareness. Any proceeds generated by purchases of facial hairstyles in Shavetopia will go directly to bolster Movember’s work in supporting mental health and suicide prevention, as well as prostate and testicular cancer awareness. In addition to partnering with Movember, Philips Norelco is also partnering with Dr. Jake Taylor, Urologic Oncology Fellow, University of Southwestern Texas Medical Center, to serve as an expert voice in the men’s health space.
“It’s so important for men to take an active role in both their physical and mental health,” said Dr. Jake Taylor. “Even just starting your day with a routine that boosts your confidence, like shaving, can make a big difference for your mental health. That’s why I’m thrilled to partner with an organization like Philips Norelco, who is actively committed to supporting both the physical and mental health for men.”
“We’re thrilled to join forces with Philips Norelco for the second consecutive year. We believe that Shavetopia will help raise awareness for men’s health issues among new audiences,” said Mark Hedstrom, Movember US Country Director. “These virtual facial hairstyles enable more people, regardless of gender or ability to grow facial hair, to show their support for Movember in ways we never thought possible.”
To participate, create an account on Roblox and check out Shavetopia in support of Movember’s efforts to improve men’s health this fall. You can also update your facial hairstyle with Philips Norelco OneBlade, the all-in-one tool that can trim, edge and shave any length of hair, available for purchase at Philips.com and major retailers.
In addition to creating Shavetopia, Philips Norelco is proud to donate $400,000 to the Movember Foundation, a 501(c)(3) non-profit organization committed to changing the face of men’s health. In addition, for every Philips Norelco & OneBlade handle sold in CVS and Walmart stores in the United States between October 1, 2022 and December 31, 2022, Philips will donate $0.50, up to $100,000, for a maximum total donation of $500,000.
About Royal Philips
Royal Philips (NYSE: PHG) (AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Movember is the leading charity changing the face of men’s health on a global scale, focusing on mental health and suicide prevention, prostate cancer and testicular cancer. The charity raises funds to deliver innovative, breakthrough research and support programs that enable men to live happier, healthier and longer lives. Committed to disrupting the status quo, millions have joined the movement, helping fund over 1,250 projects around the world. In addition to tackling key health issues faced by men, Movember is working to encourage men to stay healthy in all areas of their life, with a focus on men staying socially connected and becoming more open to discussing their health and significant moments in their lives. The charity’s vision is to have an everlasting impact on the face of men’s health. To donate or learn more, please visit movember.com.
SOURCE Philips Norelco
CONTACT: Rachel Triller, 802-855-1120, Rachel.firstname.lastname@example.org; Anna Stathopoulos, 212-805-8047, email@example.com